BACKGROUND: Concomitant use of antiretroviral (ARV) and hormonal contraceptives may change the metabolism of each and the resulting safety profiles. We evaluated the safety and tolerability of depot medroxyprogesterone acetate (DMPA) among women on ARV. STUDY DESIGN: HIV-infected women on selected ARV regimens or no ARV were administered DMPA 150 mg intramuscularly and evaluated for 12 weeks for adverse events, changes in CD4+ count and HIV RNA levels, and ovulation. RESULTS: Seventy evaluable subjects were included, 16 on nucleoside only or no ARV, 21 on nelfinavir-containing regimens, 17 on efavirenz-containing regimens and 16 on nevirapine-containing regimens. Nine Grade 3 or 4 adverse events occurred in seven subjects; none were judged related to DMPA. The most common findings possibly related to DMPA were abnormal vaginal bleeding (nine, 12.7%), headache (three, 4.2%), abdominal pain, mood changes, insomnia, anorexia and fatigue, each occurring in two (2.9%) subjects. No significant changes in CD4+ count or HIV RNA levels occurred with DMPA. No evidence of ovulation was detected, and no pregnancies occurred. CONCLUSIONS: The clinical profile associated with DMPA administration in HIV-infected women, most on ARV, appears similar to that seen in HIV-uninfected women. DMPA prevented ovulation and did not affect CD4+ counts or HIV RNA levels. In concert with previously published DMPA/ARV interaction data, these data suggest that DMPA can be used safely by HIV-infected women on the ARV studied.
BACKGROUND: Concomitant use of antiretroviral (ARV) and hormonal contraceptives may change the metabolism of each and the resulting safety profiles. We evaluated the safety and tolerability of depot medroxyprogesterone acetate (DMPA) among women on ARV. STUDY DESIGN:HIV-infectedwomen on selected ARV regimens or no ARV were administered DMPA 150 mg intramuscularly and evaluated for 12 weeks for adverse events, changes in CD4+ count and HIV RNA levels, and ovulation. RESULTS: Seventy evaluable subjects were included, 16 on nucleoside only or no ARV, 21 on nelfinavir-containing regimens, 17 on efavirenz-containing regimens and 16 on nevirapine-containing regimens. Nine Grade 3 or 4 adverse events occurred in seven subjects; none were judged related to DMPA. The most common findings possibly related to DMPA were abnormal vaginal bleeding (nine, 12.7%), headache (three, 4.2%), abdominal pain, mood changes, insomnia, anorexia and fatigue, each occurring in two (2.9%) subjects. No significant changes in CD4+ count or HIV RNA levels occurred with DMPA. No evidence of ovulation was detected, and no pregnancies occurred. CONCLUSIONS: The clinical profile associated with DMPA administration in HIV-infectedwomen, most on ARV, appears similar to that seen in HIV-uninfectedwomen. DMPA prevented ovulation and did not affect CD4+ counts or HIV RNA levels. In concert with previously published DMPA/ARV interaction data, these data suggest that DMPA can be used safely by HIV-infectedwomen on the ARV studied.
Authors: S E Cohn; J-G Park; D H Watts; A Stek; J Hitti; P A Clax; S Yu; J J L Lertora Journal: Clin Pharmacol Ther Date: 2006-12-27 Impact factor: 6.875
Authors: Helen E Cejtin; Lisa Jacobson; Gayle Springer; D Heather Watts; Alexandra Levine; Ruth Greenblatt; Kathryn Anastos; Howard L Minkoff; Leslie S Massad; Julie B Schmidt Journal: AIDS Date: 2003-07-25 Impact factor: 4.177
Authors: Ludo Lavreys; Jared M Baeten; Joan K Kreiss; Barbra A Richardson; Bhavna H Chohan; Wisal Hassan; Dana D Panteleeff; Kishorchandra Mandaliya; Jeckoniah O Ndinya-Achola; Julie Overbaugh Journal: J Infect Dis Date: 2004-01-09 Impact factor: 5.226
Authors: Sara E Dolan; Jeannie S Huang; Kathleen M Killilea; Meghan P Sullivan; Negar Aliabadi; Steven Grinspoon Journal: AIDS Date: 2004-02-20 Impact factor: 4.177
Authors: Amneris E Luque; Susan E Cohn; Jeong-Gun Park; Yoninah Cramer; Adriana Weinberg; Elizabeth Livingston; Karin L Klingman; Francesca Aweeka; D Heather Watts Journal: Antimicrob Agents Chemother Date: 2015-01-26 Impact factor: 5.191
Authors: Chelsea B Polis; Gertrude Nakigozi; Victor Ssempijja; Fredrick E Makumbi; Iga Boaz; Steven J Reynolds; Anthony Ndyanabo; Tom Lutalo; Maria J Wawer; Ronald H Gray Journal: Contraception Date: 2012-06-18 Impact factor: 3.375
Authors: Mary A Vogler; Kristine Patterson; Lori Kamemoto; Jeong-Gun Park; Heather Watts; Francesca Aweeka; Karin L Klingman; Susan E Cohn Journal: J Acquir Immune Defic Syndr Date: 2010-12 Impact factor: 3.731
Authors: Adriana Weinberg; Jeong-Gun Park; Ronald Bosch; Alice Cho; Elizabeth Livingston; Fran Aweeka; Yoninah Cramer; D Heather Watts; Amneris E Luque; Susan E Cohn Journal: J Acquir Immune Defic Syndr Date: 2016-02-01 Impact factor: 3.731
Authors: Maria Pyra; Renee Heffron; Nelly R Mugo; Kavita Nanda; Katherine K Thomas; Connie Celum; Athena P Kourtis; Edwin Were; Helen Rees; Elizabeth Bukusi; Jared M Baeten Journal: AIDS Date: 2015-11 Impact factor: 4.177